Don't Jump to Ubrelvy or Reyvow for Acute Migraine Treatment

March 2020

You'll see new oral meds to treat acute migraine in adults, Ubrelvy (yoo-BREL-vee, ubrogepant) and Reyvow (RAY-vow, lasmiditan).

Ubrelvy is the first "gepant." It blocks receptors of calcitonin gene-related peptide (CGRP), a vasodilator and pain sensitizer that spikes during migraine attacks.

It's different than the injectables for PREVENTION (Aimovig, Ajovy, Emgality)...monoclonal antibodies that block CGRP effects.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Infection Control Reinforce Infection Control in Light of Coronavirus
Migraine Don't Jump to Ubrelvy or Reyvow for Acute Migraine Treatment
Vitamins & Minerals Share the Latest Answers About Vitamin D
Vaccines Feel Comfortable Using Tdap for Routine Tetanus Vaccinations
Women's Health Stick with Tried and True Treatments for Menstrual Symptoms
Hypertension Be Ready to Manage Patients With Very High BP
Osteoarthritis Help Patients Navigate Osteoarthritis Treatments
Testosterone Weigh Risks and Benefits of Testosterone for "Low T"
Medication Errors Prevent Cases of Mistaken Med Identity
Sickle Cell Disease Watch for Adakveo or Oxbryta to Treat Sickle Cell Disease
Transitions of Care Reduce Errors During Hospital Transitions to Outside Facilities

Don't Jump to Ubrelvy or Reyvow for Acute Migraine Treatment

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents